A rare case of symmetrical drug‐related intertriginous and flexural erythema with tamoxifen use
Syed Ather Hussain, Ryan Berenji, Sarah Faisal, Liaqat Ali, Ashley Knavel
TL;DR
This paper reports a rare skin condition caused by tamoxifen, highlighting the importance of recognizing it to prevent severe complications.
Contribution
The paper presents a new case of SDRIFE linked to tamoxifen, expanding the known side effects of this drug.
Findings
SDRIFE is a rare but serious side effect of tamoxifen.
Discontinuing tamoxifen can resolve the condition.
Clinicians should be aware of this potential complication.
Abstract
Symmetrical drug‐related intertriginous and flexural erythema is characterized by a diffuse symmetric rash of the gluteal and intertriginous areas with only one published report of association with tamoxifen. It is imperative for clinicians to recognize tamoxifen‐induced SDRIFE to avoid life‐threatening dermatologic complications, which can be resolved with discontinuation of tamoxifen.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDrug-Induced Adverse Reactions · Chemotherapy-related skin toxicity · HER2/EGFR in Cancer Research